US2022185799A1PendingUtilityA1
1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
Assignee: SUNOVION PHARMACEUTICALS INCPriority: Feb 11, 2015Filed: Oct 29, 2021Published: Jun 16, 2022
Est. expiryFeb 11, 2035(~8.6 yrs left)· nominal 20-yr term from priority
C07D 413/04C07D 405/04C07D 405/14A61P 25/00A61P 25/18C07D 413/14A61K 31/4025C07D 493/04A61P 25/24A61P 25/22A61K 31/353
73
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, R a , R 1 , R 2 , R 3 , R 4 , R 6 , w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is
m is 0, 1, or 2;
n1 is 1, 2, or 3;
R is —H or C 1 -C 3 alkyl;
R a is —H or C 1 -C 3 alkyl;
R 1 , R 2 , R 3 , and R 4 are independently —H, halo, —OH, —NH 2 , C 1 -C 3 alkyl, —OR 7 , —NHR 7 , —N(R 7 )R 7 , —CN, phenyl, or 5- or 6-membered heteroaryl, wherein:
each instance of R 7 independently is unsubstituted C 1 -C 2 alkyl or C 1 -C 2 alkyl substituted with 1-3 halo,
each instance of C 1 -C 3 alkyl independently is unsubstituted or substituted with 1-3 halo, and
the phenyl or heteroaryl is unsubstituted or substituted with 1 or 2 groups independently selected from halo, —OH, —OCH 3 , —OCF 3 , —NH 2 , —NH(CH 3 ), —N(CH 3 ) 2 , —CH 3 , ethyl, —CF 3 , and —CN,
optionally wherein
two adjacent instances of R 1 , R 2 , R 3 , and R 4 together form —O—CH 2 —O—, —O—CH(CH 3 )—O—, —O—C(CH 3 ) 2 —O—, —O—CH 2 —CH 2 —O—, or —O—C(CH 3 ) 2 —C(CH 3 ) 2 —O—;
each instance of R 5 independently is halo, —CH 3 , or ethyl;
each instance of R 6 independently is halo, —CH 3 , ethyl or —OH; and
w is 0, 1, or 2.
2 . The compound of claim 1 of formula (III):
or a pharmaceutically acceptable salt thereof.
3 . The compound of claim 2 of formula (IIIa), formula (IIIb), formula (IIIc), or formula (IIId):
or a pharmaceutically acceptable salt thereof.
4 - 11 . (canceled)
12 . The compound of claim 1 of formula (I-C):
or a pharmaceutically acceptable salt thereof.
13 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n1 is 1.
14 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n1 is 2.
15 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n1 is 3.
16 . (canceled)
17 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least three of R 1 , R 2 , R 3 , and R 4 are —H.
18 - 20 . (canceled)
21 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein two adjacent instances of R 1 , R 2 , R 3 , and R 4 together form —O—CH 2 —O—, —O—CH(CH 3 )—O—, or —O—C(CH 3 ) 2 —O—.
22 . (canceled)
23 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R a is —H and/or wherein R is —H.
24 - 27 . (canceled)
28 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 0 and/or w is 0.
29 - 31 . (canceled)
32 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , and R 4 are independently —H, —F, —CH 3 , —OCH 3 , or —CN.
33 - 36 . (canceled)
37 . The compound of claim 17 , or a pharmaceutically acceptable salt thereof, wherein:
n1 is 2; R a is H; m is 0; w is 0; R is H; and R 1 , R 2 , R 3 , and R 4 are independently —H, —F, —CH 3 , —OCH 3 , or —CN.
38 . The compound of claim 1 , selected from those depicted in Table 1:
TABLE 1
I-79
I-80
I-81
I-82
I-83
I-84
I-85
I-86
I-87
I-88
I-89
I-90
I-91
I-92
I-93
I-94
I-95
I-96
I-114
I-115
I-116
I-117
I-126
I-127
I-128
I-133
I-135
I-136
I-143
I-144
or a pharmaceutically acceptable salt thereof.
39 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
40 . The compound of claim 39 , selected from:
or a pharmaceutically acceptable salt thereof, or a mixture of two or more thereof.
41 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
42 . The compound of claim 45 , selected from:
or a pharmaceutically acceptable salt thereof, or a mixture of two or more thereof.
43 . A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
44 . A method for treating a neurological or psychiatric disorder in a patient, comprising administering to said patient an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.Join the waitlist — get patent alerts
Track US2022185799A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.